{"id":"W4323652772","doi":"10.1007/s00280-023-04516-9","title":"A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Dosing; Calicheamicin; Refractory (planetary science); Pharmacokinetics; CD33; Myeloid leukemia; Internal medicine; Oncology; Pharmacology; CD34; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007578243,0.0008002258,0.001196197,0.0002290828,0.0002223932,0.000426056,0.0004491294,0.000533584,0.001282391],"category_scores_gemma":[0.000734932,0.0002850835,0.0005761692,0.0002256563,0.0005897665,0.0004044932,0.000207249,0.001555632,0.0002692139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005786924,"about_ca_system_score_gemma":0.0006791309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004882612,"about_ca_topic_score_gemma":0.0009889299,"domain_scores_codex":[0.9997187,0.0001414792,0.00001321623,0.0000515126,0.00002768179,0.0000473434],"domain_scores_gemma":[0.9995121,0.00007854032,0.0001389875,0.00005877419,0.00002493383,0.0001867288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6012199,0.05884443,0.0207394,0.0006524427,0.001549602,0.000260789,0.0004371513,0.004136644,0.1309343,0.0002403024,0.001755868,0.1792292],"study_design_scores_gemma":[0.2358302,0.7133057,0.03897133,0.00002327778,0.0004220126,0.0003072692,0.00004939345,0.001708923,0.0073167,0.0001431597,0.001899182,0.0000227591],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985294,0.0004362909,0.0002340734,0.00004592859,0.00001122717,0.000372462,0.0001057628,0.00001902874,0.0002457604],"genre_scores_gemma":[0.9977372,0.000285013,0.0006637695,0.0001301597,0.00003303033,0.0004504781,0.0003194491,0.00000772233,0.0003731157],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001282391,"threshold_uncertainty_score":0.004290044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02479243153748407,"score_gpt":0.386802173481273,"score_spread":0.3620097419437889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}